{"id":"W4412076815","doi":"10.1016/j.jtho.2025.07.009","title":"Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer","year":2025,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; University Health Network","funders":"Foundation Medicine; Loxo Oncology; Novartis Pharma; EMD Serono; Genentech; PharmaMar; European Society for Medical Oncology; Eisai; Bayer HealthCare; Relay Therapeutics; Boston Pharmaceuticals; Janssen Scientific Affairs; Takeda Oncology; Mirati Therapeutics; Teva Pharmaceutical Industries; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Associazione Italiana per la Ricerca sul Cancro; Eli Lilly and Company; National Comprehensive Cancer Network; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Celgene; BeiGene; International Association for the Study of Lung Cancer; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; American Society of Clinical Oncology; Bristol-Myers Squibb; Ariad Pharmaceuticals; Amgen; Incyte; Pfizer; LUNGevity Foundation","keywords":"Medicine; Statement (logic); Lung cancer; Association (psychology); Cancer; Family medicine; Oncology; Internal medicine; Epistemology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01543038,0.001021884,0.002610894,0.003115798,0.0009040775,0.002456405,0.003311555,0.005658918,0.003738181],"category_scores_gemma":[0.01456356,0.0005509306,0.002072068,0.002827205,0.001140343,0.002489029,0.002480976,0.007175543,0.003046501],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00270955,"about_ca_system_score_gemma":0.01270556,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00376403,"about_ca_topic_score_gemma":0.008026871,"domain_scores_codex":[0.996425,0.0009823815,0.0007570831,0.0003387495,0.001160199,0.0003366216],"domain_scores_gemma":[0.9894202,0.00364622,0.001303243,0.0002218849,0.004402121,0.001006306],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002146215,0.00008159618,0.001096887,0.01025817,0.0002603826,0.0001600564,0.00009555127,0.0002730709,0.0006212911,0.005214626,0.4626542,0.5190696],"study_design_scores_gemma":[0.00013883,0.00006157043,0.00230758,0.0162703,0.0003371197,0.0005151026,0.00009104024,0.00009205122,0.0002448524,0.00290928,0.9769961,0.00003609494],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004552926,0.8787425,0.001764814,0.09390622,0.01825403,0.0002475147,0.000776305,0.00007652972,0.005776769],"genre_scores_gemma":[0.003543473,0.929716,0.005427108,0.0454854,0.008139304,0.0004559302,0.001798082,0.00004220996,0.00539249],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01543038,"threshold_uncertainty_score":0.0816046,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03954637161951112,"score_gpt":0.5335992569666205,"score_spread":0.4940528853471093,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}